A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results